Compare Colgate-Palmolive Company (CL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Incyte Corporation — how do they compare? Colgate-Palmolive Company trades at $92.75 (market cap $73.59B), while Incyte Corporation trades at $120.67 (market cap $24.54B). The key difference: Colgate-Palmolive Company is far larger — about 3× Incyte Corporation's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CL | INCY | |
|---|---|---|
Market Cap | $73.59B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $129.93 |
52-Week Low | $74.98 | $81.61 |
Enterprise Value | $80.07B | $20.04B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $92.66, down 0.53% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by strength in Latin America and Asia Pacific, though North American performance remains weak. Operating cash flow remains robust at $4.20 billion for 2025. The stock is trading below the consensus price target of $99.10.
The outlook is mixed, with strong profitability and consistent earnings beats offset by high valuation multiples and domestic market challenges. The primary opportunity lies in international growth and margin expansion, while risks include intense competition and reliance on emerging markets for growth.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
